Clinical Research Directory
Browse clinical research sites, groups, and studies.
Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRD
Sponsor: Peking University People's Hospital
Summary
So far, MRD assessment by liquid biopsy (ctDNA) has not been used to predict postoperative treatment efficacy and recurrence risk of GIST patients because of special disease characteristics and technological limitations. Therefore, we conducted this prospective multi-center, single-arm observational study to collect 45 operable patients with locally advanced, suspected high-risk GIST. NGS genetic testing platform is used to detect tumour tissues and peripheral ctDNA will also be dectected. we try to explore the correlation between PFS/OS and MRD in high-risk GIST patients by analyzing the relationship between dynamic changes in ctDNA mutation spectrum and postoperative adjuvant therapy efficacy, and to evaluate MRD-based genomic characteristics to guide further treatment.
Official title: Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Minimal Residual Disease Detected by Liquid Biopsy
Key Details
Gender
All
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
45
Start Date
2022-01-01
Completion Date
2028-04
Last Updated
2022-09-21
Healthy Volunteers
No
Interventions
liquid biopsy
A test that enables the diagnosis or analysis of tumors using only a blood or fluid sample rather than a solid tissue biopsy.
Locations (1)
Peking University People'S Hospital
Beijing, Beijing Municipality, China